1. Medtech Insight
  2. >>Geography
  3. >>North America
  4. >>United States

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

Prez says GM "was wasting time"

 
• By Shawn M. Schmitt

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

WASHINGTON, DC - JUNE 12, 2019: President Donald Trump pauses with a serious face during a press conference in the Rose Garden of the White House with Polish President Andrzej Duda.

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, ordering auto giant General Motors Co. to make medical ventilators as the nation’s stressed health system continues to face the COVID-19 pandemic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

FDA Reverses Course, Allows Some Telework For Reviewers

 
• By Derrick Gingery

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.

Medtech Looks For Relief As Trump Hits Pause On Most Tariffs

 
• By Elizabeth Orr

The medtech industry hopes to use a 90-day pause on tariffs to negotiate a “zero for zero” exemption. However, recent public comments from President Donald Trump suggest the health care sector may still be at risk.

Biotech Leader Predicts Delays On Device Approvals As FDA Makes Life-Saving Drugs Sole Priority

 
• By Natasha Barrow

Nawal Ouzren, Sensorion CEO and director, shared the latest industry reaction to US FDA layoffs at the McDermott Will & Emery European Health and Life Sciences Symposium in Paris.

Shuren Expects Longer CDRH Review Times

 
• By Elizabeth Orr

The FDA staff cuts will probably mean longer device review times at least in the short term, speakers said at a recent webinar. But innovations like AI and third-party review could offer some hope, even as tariffs create a new set of problems.

More from North America

Shuren Expects Longer CDRH Review Times

 
• By Elizabeth Orr

The FDA staff cuts will probably mean longer device review times at least in the short term, speakers said at a recent webinar. But innovations like AI and third-party review could offer some hope, even as tariffs create a new set of problems.

Draft FDA Reorganization Would Unite All Product Centers

 
• By Sarah Karlin-Smith

Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.

End Of The Road? Court LDT Decision May Leave FDA With Few Options

 
• By Brian Bossetta

Now that a federal judge has ruled the US FDA exceeded its authority by unilaterally assuming regulatory oversight of lab-developed tests, what’s the agency’s next move? And does it really have one?